



18th International
Celiac Disease Symposium

ICDS

**SEPTEMBER
5th - 7th, 2019**

Marriott Rive Gauche
PARIS FRANCE

In association with
ISSCD  International Society for the
Study of Celiac Disease

Under the auspices of
 **SNFCG**

PROGRAM

www.icds2019-paris.com



Better Health, Brighter Future

Gastrointestinal (GI) diseases can be complex, debilitating and life-changing. That is why Takeda and our collaboration partners are committed to improving the lives of patients through the delivery of innovative medicines and dedicated patient disease support programs for over 25 years.

Takeda is leading areas of gastroenterology associated with high unmet need, such as inflammatory bowel disease, acid-related diseases and motility disorders. Our GI research & development team is also exploring treatments in celiac disease, advanced liver disease and microbiome therapies. We strive to understand the causes of these diseases and develop therapies that can ultimately advance how patients manage their condition.



Takeda Pharmaceutical Company Limited

www.takeda.com





SUMMARY

1	Edito	4
2	The board.....	5
3	Partners.....	6
4	Exhibition plan.....	7
5	Program	
6	• Thursday, September 5th	8 - 9
	• Friday, September 6th	10 - 11
	• Saturday, September 7th	12
7	Poster sessions	14 - 21
8	Practical information	23

EDITO

Dear Friends,

Eighteen very intense years separate ICDS 2002 and ICDS 2019 in Paris. Over this period, interest for coeliac disease has been blooming worldwide and ICDS has met formidable success across Europe, in the US and recently in India. Considerable efforts have been invested and have succeeded in unravelling the wide geographic distribution and increasing incidence of coeliac disease, in describing its highly versatile and changing clinical presentation, in refining diagnostic approaches. Pathophysiological studies have considerably progressed, and translation into innovative and rationale-based strategies has been initiated. New therapeutic approaches will be soon available outside gluten free diet. Beyond coeliac disease, the possible impact of dietary gluten on human health is raising considerable concern and interrogation on the reality and possible mechanisms of non-coeliac cases of gluten-driven pathology.

With the ISSCD board and of the ICDS 2019 scientific committee, we intend to make the 18th ICDS an outstanding forum for sharing expanding knowledge, for promoting education in coeliac disease and related disorders. We intend to encourage many discussions, to delineate future challenges in the field and to build and foster international cooperation. We expect that Paris will be ideal to combine first class science with pleasurable food and many romantic or cultural promenades.

Christophe Cellier and Nadine Cerf Bensussan for the Organising committee.




18th International
Celiac Disease Symposium

ICDS

SEPTEMBER
5th - 7th, 2019

Marriott Rive Gauche
PARIS FRANCE

in association with

ISSCD  International Society for the Study of Celiac Disease

Under the auspice of

 SNEGE



THE BOARD

The International Society for the Study of Celiac Disease



Pr David S Sanders
President of the ISSCD

ISSCD | International Society for the Study of Celiac Disease



Pr Christophe Cellier



Dr Govind Makharia



Pr Knut Lundin



Dr Bana Jabri



Pr Ricardo Troncone



Dr Luisa Mearin

FACULTY

Valerie Abadie	Hilary Croft	Chaitan Khosla	Philippe Marteau	Harry Sokol
Daniel Agardh	Prasenjit Das	Mikael Knip	Maria Luisa Mearin	Patrick Tounian
Bob Anderson	Fleur Du Pre	Tunde Koltai	Thierry Molina	Riccardo Troncone
Carin Andren Aronsson	Knut E. A. Lundin	Ilma Korponay-Szabo	Chris Mulder	Nick Trott
Renata Auricchio	Linn Eggesbo	Frits Koning	Joseph Murray	Christel Turcat
Julio Bai	Luca Elli	Alain Lachaux	Hugo Penny	Heidi Urwin
Julie Bruneau	Alain Fischer	Benjamin Lebwohl	Jean-Marie Peron	Elena Verdu
Carlo Catassi	Peter Green	Dan Leffler	Lluis Quintana-Murci	Umberto Volta
Angel Cebolla	Marios Hadjivassiliou	Ida Lindeman	Gabriel Rahmi	David Wraith
Christophe Cellier	Melinda Hardy	Katri Lindfors	Maxime-Dominique Rouvroye	Maria Zorro
Nadine Cerf-Bensussan	Olivier Hermine	Elena Lionetti	David Sanders	Stephanie Zühlke
Juliana Cerqueira	Bana Jabri	Jonas Ludvigsson	Katharina Scherf	
Fabienne Charbit-Henriton	Iris Jonkers	Ludvig M. Sollid	Detlef Schuppan	
Carolina Ciacci	Pauline Jouet	Govind Makharia	David Sibon	
Sascha Cording	Sherine Khater	Markku Mäki		

REVIEWERS

ICDS 2019 would like to express its special thanks to the abstract reviewers, which played an important role in the appreciation of the research abstracts.

Dr. Daniel Agardh	Pr. Peter Green	Pr. Maria Luisa Maerin
Dr. Bob Anderson	Dr. Stefano Guandalini	Pr. Chris Mulder
Dr. Renata Auricchio	Pr. Frits Koning	Pr. Joseph Murray
Pr. Julio Bai	Dr. Kalle Kurppa	Pr. David Sanders
Pr. Christophe Cellier	Dr. Benjamin Lebwohl	Pr. Detlef Schuppan
Dr. Nadine Cerf-Bensussan	Pr. Knut E. A. Lundin	Pr. Riccardo Troncone
Pr. Carolina Ciacci	Pr. Ludvig M. Sollid	Pr. Umberto Volta
Dr. Paula Crespo	Pr. Govind Makharia	Dr. Margreet Wessels



PARTNERS 2019

PLATINIUM



GOLD



SILVER




PARTNERS






EXHIBITION PLAN



VENUE LAYOUT





THURSDAY, SEPTEMBER 5TH, 2019

SCIENTIFIC FORUM - ROOM SCENE - LEVEL 0

08:15 - 08:30 am	Welcome remarks
08:30 - 10:00 am	Update in celiac disease diagnosis Chairpersons: David Sanders , <i>Sheffield, United-Kingdom</i> ; Alain Lachaux , <i>Lyon, France</i>
08:30 - 08:50 am	Celiac disease diagnosis in adults: update Knut E. A. Lundin , <i>Oslo, Norway</i>
08:50 - 09:10 am	Celiac diagnosis in children: new ESPGHAN criteria guidelines Riccardo Troncone , <i>Naples, Italy</i>
09:10 - 09:30 am	Mass screening vs targeted screening: update Maria Luisa Mearin , <i>Leiden, Netherlands</i>
09:30 - 09:40 am	Phospholipid profile at 4 months of age predicts the onset of celiac disease in at risk infants. Renata Auricchio , <i>Naples, Italy</i>
09:40 - 09:50 am	How long should children with a first-degree coeliac relative be followed and screened? Ilma Korponay-Szabo , <i>Debrecen, Hungary</i>
09:50 - 10:00 am	Mass Screening for celiac disease in school-age children: the CELI-SCREEN multicenter study. Elena Lionetti , <i>Ancona, Italy</i>
10:00 - 10:30 am	Coffee break
10:30 - 12:00 pm	Omics approaches in celiac disease Chairpersons: Iris Jonkers , <i>Groningen, Netherlands</i> ; Nadine Cerf-Bensussan , <i>Paris, France</i>
10:30 - 11:00 am	Genetic and environmental factors driving immune response variation in humans Lluís Quintana-Murci , <i>Paris, France</i>
11:00 - 11:30 am	Understanding celiac disease from a genetic point of view Iris Jonkers , <i>Groningen, Netherlands</i>
11:30 - 11:40 am	Independent and cumulative effects of celiac disease susceptibility loci differentially contribute to various clinical phenotypes Juliana Cerqueira , <i>Tampere, Finland</i>
11:40 - 11:50 am	Kinetics and transcriptomics of gluten-specific T cells in blood after gluten challenge Stephanie Zühlke , <i>Oslo, Norway</i>
11:50 - 12:00 pm	NMR based Metabonomics of Intestinal Mucosal Biopsies, Blood and Urine to Identify Potential Biomarker(s) for Celiac Disease Govind Makharia , <i>New Delhi, India</i>

12:15 - 01:45 pm Lunch & Symposium sponsored by Provention Bio



12:15 - 01:45 pm	Interleukin-15 (IL-15) in celiac disease and therapeutic potential of the anti-IL-15 antibody PRV-015/AMG 714 Chairperson: David Sanders , <i>Sheffield, United Kingdom</i>
12:15 - 12:30 pm	Unmet need in celiac disease - Patients' views Marilyn Geller , <i>Los Angeles, United States</i>
12:30 - 12:45 pm	Role of interleukin 15 (IL-15) in celiac disease Bana Jabri , <i>Chicago, United States</i>
12:45 - 01:00 pm	Targeting IL-15 in celiac disease (results of CELIM-NRCD-001 trial) Markku Mäki , <i>Tampere, Finland</i>
01:00 - 01:15 pm	Targeting IL-15 in refractory celiac disease (results of CELIM-RCD-002 trial) Christophe Cellier , <i>Paris, France</i>
01:15 - 01:30 pm	Next steps for anti-IL-15 (PRV-015/AMG 714) as a therapeutic for celiac disease Francisco Leon , <i>Washington DC, United States</i> Prista Charuworn , <i>San Francisco, United States</i>
01:30 - 01:45 pm	Q&A David Sanders , <i>Sheffield, United Kingdom</i>
01:45 - 03:30 pm	Pathogenesis I Chairpersons: Ludvig M.Sollid , <i>Oslo, Norway</i> ; Bana Jabri , <i>Chicago, United States</i>
01:45 - 02:10 pm	Adaptive Immunity in celiac disease: from pathogenesis to diagnosis? Ludvig M.Sollid , <i>Oslo, Norway</i>
02:10 - 02:35 pm	Innate immunity in celiac disease? Bana Jabri , <i>Chicago, United States</i>
02:35 - 03:00 pm	From autoimmunity to lymphomagenesis in celiac disease Nadine Cerf-Bensussan , <i>Paris, France</i>
03:00 - 03:10 pm	Tissue alarmins and adaptive cytokine induce dynamic and distinct transcriptional responses in tissue-resident intraepithelial cytotoxic T lymphocytes Maria Zorro , <i>Groningen, Netherlands</i>
03:10 - 03:20 pm	The intraepithelial tcr repertoire is more diverse in coeliac disease patients than in healthy subjects Linn Eggesbo , <i>Oslo, Norway</i>
03:20 - 03:30 pm	B-cell tolerance and antibody production to the celiac disease autoantigen transglutaminase 2 (TG2) Fleur Du Pre , <i>Oslo, Norway</i>
03:30 - 04:00 pm	Coffee break
04:00 - 04:40 pm	Keynote lecture Chairperson: Bana Jabri , <i>Chicago, United States</i> ; Autoimmunity: lessons from human immunodeficiencies Alain Fisher , <i>Paris, France</i>
04:40 - 06:00 pm	Drink and Posters

THURSDAY, SEPTEMBER 5TH, 2019



CLINICAL FORUM - ROOM FORUM - LEVEL -1

08:15 - 12:30 pm	SNFGE French Symposium Chairperson: Jean-Marie Peron , <i>Toulouse, France</i>
08:20 - 10:00 am	Maladie coeliaque : physiopathologie, diagnostic et traitement Chairpersons: Jean-Marie Peron , <i>Toulouse, France</i> ; Philippe Marteau , <i>Paris, France</i>
08:20 - 08:40 am	Physiopathologie de la maladie coeliaque Bana Jabri , <i>Chicago, United States</i>
08:40 - 09:00 am	Physiopathologie des complications malignes de la maladie coeliaque Nadine Cerf-Bensussan , <i>Paris, France</i>
09:00 - 09:20 am	Diagnostic et traitement de la maladie coeliaque Christophe Cellier , <i>Paris, France</i>
09:20 - 09:40 am	Hypersensibilité au gluten : mythe ou réalité Sherine Khater , <i>Paris, France</i>
09:40 - 10:00 am	Diagnostic histologique des complications de la maladie coeliaque Julie Bruneau , <i>Paris, France</i> ; Thierry Molina , <i>Paris, France</i>
10:00 - 10:30 am	Coffee break
10:30 - 12:30 pm	Maladies associées et nouveaux traitements Chairpersons: Pauline Jouet , <i>Paris, France</i> ; Patrick Tounian , <i>Paris, France</i>
10:30 - 10:50 am	Indication du régime sans gluten et autres régimes (FODMAPs) Pauline Jouet , <i>Paris, France</i>
10:50 - 11:10 am	Maladie coeliaque de l'enfant: spécificités et transition Alain Lachaux , <i>Lyon, France</i>
11:10 - 11:30 am	Intolérances alimentaires chez l'enfant Patrick Tounian , <i>Paris, France</i>
11:30 - 11:50 am	Maladies hépatiques et pancréatiques et maladie coeliaque Jean-Marie Peron , <i>Toulouse, France</i>
11:50 - 12:10 pm	Classification et traitement des lymphomes associés à la maladie coeliaque David Sibon , <i>Paris, France</i>
12:10 - 12:30 pm	Microbiote et physiopathologie de l'intestin grêle Philippe Marteau , <i>Paris, France</i>

12:30 - 01:45 pm	Poster session
01:45 - 03:35 pm	Epidemiological and diagnostic update in celiac disease Chairpersons: Carlo Catassi , <i>Ancona, Italy</i> ; Philippe Marteau , <i>Paris, France</i>
01:45 - 02:05 pm	The global village of celiac disease Carlo Catassi , <i>Ancona, Italy</i>
02:05 - 02:25 pm	The Indian and Asian perspective Govind Makharia , <i>New Delhi, India</i>
02:25 - 02:45 pm	Diagnostic and biopsy strategy David Sanders , <i>Sheffield, United-Kingdom</i>
02:45 - 03:05 pm	Antibody negative villous atrophy Joseph Murray , <i>Rochester, United States</i>
03:05 - 03:20 pm	Making a diagnosis of celiac disease in children Maria Luisa Mearin , <i>Leiden, Netherlands</i>
03:20 - 03:35 pm	How to organise transition for young celiac? Carolina Ciacci , <i>Salerno, Italy</i>
03:35 - 04:00 pm	Coffee break
04:00 - 05:40 pm	Endoscopy and celiac disease Chairpersons: Jean-Marie Peron , <i>Toulouse, France</i> ; Gabriel Rahmi , <i>Paris, France</i>
04:00 - 04:20 pm	Videocapsule in celiac disease Luca Elli , <i>Milano, Italy</i>
04:20 - 05:00 pm	Role of device assisted enteroscopy in celiac disease Sherine Khater , <i>Paris, France</i>
05:00 - 05:20 pm	Novel endoscopy recognition of celiac disease (magnification, NBI, BLI, etc) Gabriel Rahmi , <i>Paris, France</i>
05:20 - 05:40 pm	Which work-up for suspicion of malignancy in celiac disease? Chris Mulder , <i>Amsterdam, Netherlands</i>
04:40 - 06:00 pm	Drink and Posters



FRIDAY, SEPTEMBER 6TH, 2019

SCIENTIFIC FORUM - ROOM SCENE - LEVEL 0

08:00 - 08:40 am	Keynote Lecture: The interplay between genetics and environment in type I diabetes Chairpersons: Daniel Agardh , Lund, Sweden; Mikael Knip , Helsinki, Finland
08:40 - 10:00 am	Epidemiology & environmental triggers Chairpersons: Daniel Agardh , Lund, Sweden; Elena Verdu , Ontario, Canada
08:40 - 09:00 am	Natural history of celiac disease: lessons from at risk pediatric cohorts Daniel Agardh , Lund, Sweden
09:00 - 09:20 am	Mechanistic insight into the role of microbiota in intestinal inflammation Harry Sokol , Paris, France
09:20 - 09:40 am	Environmental factors: update on the role of gut microbiota in celiac disease Elena Verdu , Ontario, Canada
09:40 - 09:50 am	Metagenomic analysis of fecal virome identifies specific enteroviruses and adenoviruses as potential triggers of celiac disease autoimmunity in the TEDDY study Katri Lindfors , Tampere, Finland
09:50 - 10:00 am	Gluten intake and risk of celiac disease Carin Andren Aronsson , Malmo, Sweden
10:00 - 10:30 am	Coffee break
10:30 - 12:00 pm	Pathogenesis II Chairpersons: Frits Koning , Leiden, Netherlands; Detlef Schuppan , Mainz, Germany
10:30 - 10:50 am	Lessons from animal models in celiac disease Valerie Abadie , Chicago, United States
10:50 - 11:10 am	ATI proteins, celiac disease and gluten hypersensitivity Detlef Schuppan , Mainz, Germany
11:10 - 11:30 am	Innovative approaches to investigate human gut immune cells in celiac disease? Frits Koning , Leiden, Netherlands
11:30 - 11:40 am	Characterisation of Clinical and Immune Reactivity to Barley and Rye Consumption in Children with Celiac Disease Melinda Hardy , Melbourne, Australia
11:40 - 11:50 am	Simultaneous transcriptional characterisation and clonal inference of disease-specific plasma cells in coeliac disease Ida Lindeman , Oslo, Norway
11:50 - 12:00 pm	The genetic landscape of type II Refractory Celiac Disease and Enteropathy Associated T-Cell Lymphoma reveals recurrent activating mutations of the JAK1/STAT3 axis Sascha Cording , Paris, France
12:00 - 01:45 pm	Lunch & poster session
12:20 - 01:35 pm	Symposium sponsored by Takeda
12:20 - 01:35 pm	Imagining the future: how will the celiac disease patient journey change over the next 10 years?

12:20 - 12:25 pm	Welcome and introduction Dan Leffler , Boston, United States
12:25 - 12:40 pm	Will there be a role for endoscopy and biopsy in the diagnosis of celiac disease in 10 years? David Sanders , Sheffield, United Kingdom
12:40 - 12:55 pm	Will we still be talking about the Gluten-Free diet in 2030? Maureen Leonard , Boston, United States
12:55 - 01:10 pm	Will novel technologies revolutionise the way we monitor celiac disease? Luca Elli , Milano, Italy
01:10 - 01:30 pm	Panel discussion and Q&A
01:30 - 01:35 pm	Summary and close Dan Leffler , Boston, United States
01:45 - 03:15 pm	Refractory celiac disease, Non celiac disease enteropathies & intestinal lymphomas Chairpersons: Christophe Cellier , Paris, France; Chris Mulder , Amsterdam, Netherlands
01:45 - 02:00 pm	Diagnosis and treatment of refractory celiac disease Christophe Cellier , Paris, France
02:00 - 02:15 pm	Diagnosis and treatment of non responsive celiac disease Chris Mulder , Amsterdam, Netherlands
02:15 - 02:35 pm	Non celiac disease associated enteropathies and lymphomas Joseph Murray , Rochester, United States
02:35 - 02:55 pm	New classification of T intestinal cell lymphoma and targeted treatments Olivier Hermine , Paris, France
02:55 - 03:05 pm	Non-responsive and Refractory Coeliac Disease: The Largest UK Experience from the NHS England Rare Diseases Collaborative Network Hugo Penny , Sheffield, United Kingdom
03:05 - 03:15 pm	Characterization of a large cohort of children with non-celiac auto-immune enteropathies Fabienne Charbit-Henriton , Paris, France
03:15 - 03:45 pm	Coffee break
03:45 - 05:05 pm	The spectrum of gluten associated diseases Chairpersons: Peter Green , New-York, United States; Sheila Crowe , San Diego, United States
03:45 - 04:05 pm	Gluten hypersensitivity: myth and reality? Peter Green , New-York, United States
04:05 - 04:25 pm	Has gluten recently changed in composition or processing? The agronomist's view Katharina Scherf , Freising, Germany
04:25 - 04:45 pm	Extraintestinal manifestations of celiac disease or celiac disease associated diseases Jonas Ludvigsson , Stockholm, Sweden
04:45 - 04:55 pm	Post-Mortem Immuno-Pathological Findings in the Cerebellum of Celiac Disease patients with concomitant Idiopathic Neurological Disorder Maxine-Dominique Rouvroye , Amsterdam, Netherlands
04:55 - 05:05 pm	IgA anti-tTG co-localization for identification of Celiac Associated Liver Diseases Prasenjit Das , New Delhi, India
05:05 - 06:00 pm	Drink and Posters

FRIDAY, SEPTEMBER 6TH, 2019



CLINICAL FORUM - ROOM FORUM – LEVEL -1

08:00 - 09:15 am	Difficult diagnosis Chairpersons: Julio Bai , Buenos Aires, Argentina; Julie Bruneau , Paris, France
08:00 - 08:15 am	A patient with positive serology and normal duodenal biopsy Govind Makharia , New Delhi, India
08:15 - 08:30 am	Histological uncertainties including patients with IEL only on duodenal biopsy Umberto Volta , Bologna, Italy
08:30 - 08:45 am	Difficult histological diagnosis: RCD or lymphoma? Julie Bruneau , Paris, France
08:45 - 09:00 am	What to do in a patient already on a GFD? Julio Bai , Buenos Aires, Argentina
09:00 - 09:15 am	Villous atrophy and negative serology or negative HLA-DQ2/8 Carolina Ciacci , Salerno, Italy
09:15 - 10:30 am	Symposium sponsored by Dr. Schär



09:15 - 10:30 am	Patient management in gluten-related disorders: From the best diagnosis to the best diet Chairpersons: Christophe Cellier , Paris, France; Carlo Catassi , Ancona, Italy
09:15 - 09:25 am	Differential diagnose in GRD: keys of a good patient management David Sanders , Sheffield, United Kingdom
09:25 - 09:40 am	A GFD is not equal to a GFD: Quality of the diet for quality of life Nick Trott , Sheffield, United Kingdom
09:40 - 09:55 am	Follow up of the patient: which balance for the best compliance? Benjamin Lebwohl , New-York, United States
09:55 - 10:05 am	Nutritional profiles compared: processed GF food and their gluten containing equivalents (or counterparts) Paula Crespo Valladolid, Spain
10:05 - 10:15 am	Re-Cereal : an innovative project to improve products' quality Veronica Marin , Trieste, Italy
10:15 - 10:30 am	Questions & Answers
10:00 - 10:30 am	Coffee break
10:45 - 12:05 pm	The gluten free diet beyond the gut Chairpersons: Joseph Murray , Rochester, United States; Carolina Ciacci , Salerno, Italy
10:45 - 11:10 am	State-of-the-art lecture: the gluten free diet: safe or dangerous? Benjamin Lebwohl , New-York, United States
11:10 - 11:25 am	Are there nutritional consequences of a gluten free diet? Nick Trott , Sheffield, United-Kingdom

11:25 - 11:40 am	The gluten free diet in neurological disease Marios Hadjivassiliou , Sheffield, United-Kingdom
11:40 - 12:05 pm	State-of-the-art lecture: assessing adherence many questions no answers? Julio Bai , Buenos Aires, Argentina
12:10 - 01:45 pm	Lunch & poster session
01:45 - 03:00 pm	Non-celiac gluten sensitivity & IBS and IBD Chairpersons: Knut E A Lundin , Oslo, Norway; Umberto Volta , Bologna, Italy
01:45 - 02:05 pm	State-of-the-art lecture: how the microbiome will change our practice? Harry Sokol , Paris, France
02:05 - 02:25 pm	Update on pathogenesis of NCGS Knut E A Lundin , Oslo, Norway
02:25 - 02:45 pm	IBS GFD and FODMAPs Sherine Khater , Paris, France
02:45 - 03:00 pm	NGCS, celiac disease and IBS: how to differentiate? Umberto Volta , Bologna, Italy
03:00 - 03:45 pm	Coffee break
03:45 - 05:00 pm	New developments in celiac disease Chairpersons: Dan Leffler , Boston, United states; Maria Luisa Maerin , Leiden, Netherlands
03:45 - 04:05 pm	How to organize a celiac disease center? Chris Mulder , Amsterdam, Netherlands
04:05 - 04:20 pm	Do adult celiac patients need Vitamin D supplementation? Carolina Ciacci , Salerno, Italy
04:20 - 04:40 pm	Prevention of celiac disease: is it possible? Riccardo Troncone , Naples, Italy
04:40 - 05:00 pm	Round table : The evolving role of patient advocacy groups Heidi Urwin , Buckinghamshire, United Kingdom; Christel Turcat , Paris, France Tunde Koltai , Brussels, Belgium Hilary Croft , Bucks, United Kingdom
05:05 - 06:00 pm	Drink and Posters



SATURDAY, SEPTEMBER 7TH, 2019

SCIENTIFIC FORUM - ROOM SCENE - LEVEL 0

08:00 - 09:30 am	Novel development for diagnosis and follow-up of celiac disease Chairpersons: Markku Mäki , Tampere, Finland; Govind Makharia , New Delhi, India
08:00 - 08:40 am	Round Table : Which biomarkers to use in 2019? Markku Mäki , Tampere, Finland; Govind Makharia , New Delhi, India Topic Introduction, where do we need biomarkers Markku Mäki , Tampere, Finland Classification of biomarkers, and non-immunological biomarkers Govind Makharia , New Delhi, India Serum antibodies as biomarkers Ilma Korponay-Szabo , Debrecen, Hungary Immunological biomarkers Ludvig M.Sollid , Oslo, Norway GIP Angel Cebolla , Seville, Spain Lipids to predict onset of CD Renata Auricchio , Naples, Italy Biomarkers for refractory type II celiac disease Julie Bruneau , Paris, France Discussion and interaction with Audience
08:40 - 09:30 am	Food safety with the GFD Chairpersons: Julio Bai , Buenos Aires, Argentina Umberto Volta , Bologna, Italy
08:40 - 08:55 am	Food safety with the GFD and benefit of nutritional support? Benjamin Lebwohl , New-york, United States
08:55 - 09:10 am	Gluten diet in 2019? Unmet needs? Nick Trott , Sheffield, United Kingdom
09:10 - 09:30 am	Round table: Umberto Volta , Bologna, Italy; Knut E. A. Lundin , Oslo, Norway Psychological issues Carolina Ciacci , Salerno, Italy IBS-like symptoms, nutritional deficiencies and metabolic syndrome Luca Elli , Milano, Italy Educational training in newly diagnosed celiacs David Sanders , Sheffield, United Kingdom Non dietary therapies Peter Green , New-York, United States
09:30 - 10:00 am	Coffee break

AUDITORIUM - LEVEL -1



08:30 - 09:30 am :
Update on larazotide acetate:
Currently in 1st ever P3 trial for celiac disease
 Steve Laumas, New-York, United States

10:00 - 10:50 am	 Immunotherapy sponsored by ImmusanT
10:00 - 10:30 am	Immunotherapy antigen-specific in autoimmune diseases David Wraith , Birmingham, United Kingdom
10:30 - 10:50 am	Immunotherapy in celiac disease Bob Anderson , Cambridge, United States
10:50 - 11:55 am	New development in the treatment of celiac disease Chairpersons: Chaitan Khosla , Stanford, United States; Knut E. A. Lundin , Oslo, Norway
10:50 - 11:15 am	New therapies for celiac disease: overview Chaitan Khosla , Stanford, United States
11:15 - 11:25 am	Tolerogenic Immune-Modifying Nanoparticles Containing Gliadin Restore Tolerance and Abrogate Disease in Murine Models of Coeliac Disease Tobias Freitag , Helsinki, Finland
11:25 - 11:35 am	Absence of clinical symptoms and negative serological tests could not predict gut mucosal recovery in celiac patients. Correlation of gut mucosal damage with the presence of urine gluten peptides Angel Cebolla-Ramirez , Seville, Spain
11:35 - 11:55 am	Round table: the future of new therapies Chaitan Khosla , Stanford, United States Dan Leffler , Boston, United States Detlef Schuppan , Mainz, Germany Christophe Cellier , Paris, France The pipeline: what has entered clinical trials (TG2, nanoparticles), what survives (latiglutenase, larazotide), what is being repurposed in the clinic (anti-IL15, anti-a4b7, montelukast), and what has dropped out from clinical trials (verciron, Nexvax2, Necator americanus) What constitutes early proof-of-concept in the clinic? What labels are appropriate for registration?
11:55 - 12:15 pm	Sum up of the congress Chairpersons: Joseph Murray , Rochester, United States
12:15 - 12:30 pm	Prizes for posters and oral communication Conclusion Nadine Cerf-Bensussan , Paris, France Christophe Cellier , Paris, France



INNOVATE
Biopharmaceuticals

Focused on Autoimmune and Inflammatory Diseases

*Visit our website for information on our
celiac disease program and pipeline:*

www.innovatebiopharma.com

Innovate wishes the delegates of the
18th International Celiac Disease Symposium
a successful conference



SEPTEMBER
5th - 7th, 2019

Marriott Rive Gauche
PARIS FRANCE



POSTER SESSIONS

DIAGNOSIS

TOUR 1: THURSDAY, SEPTEMBER 5TH FROM 12:30 PM TO 01:30 PM

POSTER TOUR LEADERS:

Sherine Khater, Paris, France

Julie Bruneau, Paris, France

Elena Lionetti, Ancona, Italy

Prasenjit Das, New Delhi, India

Maxine Dominique Rouvroye, Amsterdam, Netherlands

- P1-01** Is it a biased association? Review of the co-prevalence of eosinophilic esophagitis and celiac disease.
Jennifer Hong, Baltimore, United States
- P1-02** Don't jump into the Marsh: Awareness of Celiac Disease overdiagnosis in adult community practices
Runa Watkins, Baltimore, United States
- P1-03** Blood AND Guts? - Improving the Diagnostic Accuracy for Celiac Disease
Richard Charlesworth, Armidale, Australia
- P1-04** The Predictive Value of Serum Cytokines for Distinguishing Celiac Disease from non-celiac gluten sensitivity and healthy subjects
Mohammad Rostaminejad, Tehran, Iran
- P1-05** Intestinal transglutaminase 3 and transglutaminase 2-specific plasma cell responses in dermatitis herpetiformis patients undergoing a gluten challenge
Minna Hietikko, Tampere, Finland
- P1-06** Intestinal transglutaminase 3 and transglutaminase 2-specific plasma cell responses in dermatitis herpetiformis patients undergoing a gluten challenge
Katri Lindfors, Tampere, Finland
- P1-07** Inter and Intra-assay variation in the diagnostic performance of anti-tissue transglutaminase antibody assays in two ethnic population
Govind Makharia, New Delhi, India
- P1-08** Automated Analyzers are Suited for Diagnosing Celiac Disease Following the ESPGHAN 2012 Criteria
Raanan Shamir, Petach Tikva, Israel
- P1-09** Diagnostic Yield of Small Bowel Ultrasonography compared to Video Capsule Endoscopy for the diagnosis of complicated Celiac Disease
Andrea Costantino, Milano, Italy
- P1-10** The impact of clinical presentation of celiac disease on diagnostic delays in children in Central Europe
Petra Riznik, Maribor, Slovenia
- P1-11** The influence of diagnostic delays on growth of children with celiac disease in Central Europe
Petra Riznik, Maribor, Slovenia
- P1-12** Positive Celiac Disease serology in risk groups: a diagnostic challenge.
Ester Donat, Valencia, Spain
- P1-13** The occurrence of gluten associated antibodies and the level of I-FABP in adult patients with diarrhea-predominant irritable bowel syndrome
Joanna Bierla, Warsaw, Poland
- P1-14** Nutritional quality of a gluten-free diet at low content of FODMAP in patients with Celiac Disease
Alice Scricciolo, Milano, Italy
- P1-15** Overlooked Celiac Crisis in Children in the World of Changing Clinical Patterns
Cristina Ungureanu, Bucharest, Roumania
- P1-16** Gliadin Specific Peripheral T Cell Response In Dermatitis Herpetiformis Patients Undergoing A Gluten Challenge: A Biomarker For Predicting Clinical Relapse?
Esko Kemppainen, Tampere, Finland
- P1-17** Celiac Disease in Patients with Cirrhosis and Hypertansaminasemia: A Systematic Review and Meta-analysis
Shakira Yoosuf, Boston, United States
- P1-18** Prevalence and Diagnostic Outcomes of Seronegative Villous Atrophy in Children
Marleena Repo, Tampere, Finland
- P1-19** Assessment of celiac disease severity by video capsule endoscopy with the celiac enteropathy - villous atrophy scale (CE-VAST)
Jenifer Siegelman, Cambridge, United States
- P1-20** Celiac disease and associated dermatological manifestations : a study of 280 patients
Ferdaouss Lamarti, Rabat, Morocco
- P1-23** Endoscopy to Evaluate Suspected Celiac, is Visual Assessment of Esophagus and Stomach Enough?
Maria Cristina Pacheco, Seattle, United States
- P1-24** The Utility of IgA Based Serologic Markers in Diagnosing Celiac Disease in Children ≤24 Months of Age
Imad Absah, Rochester, United States
- P1-25** Celiac disease and reproductive disorders: correlation and evolution under gluten-free diet
Manal Mahmoudi, Rabat, Morocco
- P1-26** Is celiac disease a cause of venous thrombosis? Experience of a Moroccan university department.
Soukaina Zertiti, Rabat, Morocco
- P1-27** Significance of the severity of diagnostic lesion in pediatric celiac disease: do we need the biopsy for prognostic reasons?
Sofia Kröger, Tampere, Finland
- P1-28** Dermatitis Herpetiformis in Childhood and Linking Dermopathy to Enteropathy
Arunjot Singh, Philadelphia, United States
- P1-31** Is there any correlation between serology and histology in celiac disease...?
Manal Mahmoudi, Rabat, Morocco
- P1-32** Comparison between axial and lateral/panoramic view capsule endoscopy in patients with celiac disease: results from a prospective randomized study
Luca Elli, Milano, Italy
- P1-33** Compliance With Guideline Recommended Biopsy Protocol In Consecutive Incident Cases Of Celiac Disease: A Retrospective Study From A Tertiary Care Institution
William Kessler, Indianapolis, United States
- P1-34** High prevalence of irritable bowel syndrome diagnosis in patients referred to Adult Celiac Disease Clinic - lack of knowledge of differential diagnosis or insufficient recognition of guidelines?
Silvija Cukovic-Cavka, Zagreb, Croatia

POSTER SESSIONS



- P1-35** Comparative performance of commercial diagnostic antibody tests in celiac disease patients with and without intestinal abnormalities
Daan Castelijin, Amsterdam, Netherlands
- P1-36** The Impact of gluten challenge with different doses of gluten in patients with irritable bowel syndrome
Mohammad Rostami-Nejad, Tehran, Iran
- P1-37** How low FODMAP gluten free diet affect the anxiety level in patients with irritable bowel syndrome?
Mohsen Norouzinia, Tehran, Iran
- P1-38** Neurocognitive and Behavioral Functioning Following Initiation of a Gluten Free Diet in Children with Celiac Disease
Lesley Small-Harary, Stony Brook, United States
- P1-40** Neurocognitive effects of gluten exposure: Qualitative results of a nationwide survey
Alice Bast, Ambler, United States
- P1-41** CELIAC RELATED HEPATITIS - do we recognize the problem?
Ivana Knezevic Stromar, Zagreb, Croatia
- P1-42** A Case for Early Diagnosis of Celiac Disease & its Potential to Prevent Co-Existing Autoimmune Conditions
Patricia Bierly, Philadelphia, United States
- P1-43** Titanium modified electrodes for gluten detection in food
Cristina Dumitriu, Bucharest, Roumania
- P1-44** Celiac disease patients have lower sense of coherence score than healthy controls
Efrat Broide, Zefifne, Israel
- P1-45** ESPGHAN Guidelines for Diagnosis of Celiac Disease 2019
Steffen Husby, Odense C, Germany
- P1-47** MED ABOUT DATA HACKATHON – Making Early Diagnosis of Celiac Disease Possible
Liat Kosovich, Haifa, Israel
- P1-48** Assessment of new biomarkers for diagnosis and monitoring of celiac disease
Erika Monguzzi, Mainz, Germany
- P1-49** Global consensus on definition and histological classification of non-celiac gluten sensitivity.
Kamran Rostami, Palmerston North, New Zealand
- P1-50** The use of biopsy and "no-biopsy" approach for diagnosing paediatric celiac disease in the Central European region
Petra Riznik, Maribor, Slovenia
- P1-51** Appropriate Screening for Celiac Disease at a Children's Hospital Results in Increased Testing and Decreased Charges
Michael Bates, Dayton, United States
- P1-52** Time trends of the clinical presentation and diagnosis of celiac disease
Thora Marie Høegh-Andersen, Odense, Denmark
- P1-53** Positive Predictive Value of the new generation celiac rapid test, for screening in healthy school children.
Manoubia Bensmina, Algiers, Algeria

EPIDEMIOLOGY/DIAGNOSTIC

TOUR 2: THURSDAY, SEPTEMBER 5TH FROM 05:00 PM TO 06:00 PM

POSTER TOUR LEADERS:

Renata Auricchio, *Naples, Italy*
Ritu Verma, *Chicago, United States*
Gerd Bouma, *Amsterdam, Netherlands*
Paula Crespo, *Valladolid, Spain*

- P2-01** Long-term consequences of undiagnosed celiac disease
Line Lund Kärhus, Copenhagen, Denmark
- P2-02** No Association Between HLA-DQA1*05 and -DQB1*02 Gene Dosage and Clinical Phenotype of Celiac Disease
Hugo Penny, Sheffield, United Kingdom
- P2-03** Should we be Diagnosing Celiac Disease in the Elderly?
Hugo Penny, Sheffield, United Kingdom
- P2-04** High Rates of Testing for Celiac Disease Serology, and Low Rates of Endoscopy in a Large Real-World Database
Raanan Shamir, Petach Tikva, Israel
- P2-05** Overall and Cause-Specific Mortality in Adult Celiac Disease: Population-Based Study in Contemporary Era
Inka Koskinen, Tampere, Finland
- P2-06** Patient burden and treatment experience in celiac disease
Daniel A. Leffler, Cambridge, United States
- P2-09** Immunogenetic polymorphisms in celiac disease in patients from Morocco
Soukaina Zertiti, Rabat, Morocco
- P2-10** Understanding celiac disease outcomes and monitoring patterns after diagnosis: a multinational study
Daniel A. Leffler, Boston, United States
- P2-11** Assessing severity and healthcare resource utilization in celiac disease: a U.S. claims data analysis
Daniel A. Leffler, Boston, United States
- P2-12** Undiagnosed celiac disease in women with recurrent reproductive failure
Concepción Núñez, Madrid, Spain
- P2-13** Economic burden of celiac disease in the U.S.
Song Wang, Cambridge, United States
- P2-14** Adherence to the gluten-free diet and patient outcomes: Real world evidences from an international patient registry, iCureCeliac
Kristina Chen, Cambridge, United States
- P2-15** The knowledge of medical professions on celiac disease in opinion of Polish patients with celiac disease
Emilia Majsiaik, Lublin, Poland
- P2-16** The frequency of testing and diagnosing with CD family members of Polish patients with confirmed CD
Emilia Majsiaik, Lublin, Poland



POSTER SESSIONS

- P2-17** The changes in manner of diagnosing CD among Polish children
Emilia Majsiaik, Lublin, Poland
- P2-18** The bottom of the Celiac Disease (CD) iceberg: a disease still underestimated in Rome
Italo De Vitis, Roma, Italy
- P2-19** Distribution of HLA-DQ2 and HLA-DQ8 alleles in native South Indian population
Anil Verma, Ancona, Italy
- P2-20** Adult celiac disease patients diagnosed in early childhood have less comorbidities but poorer self-perceived health than those diagnosed later
Sara Koskimaa, Tampere, Finland
- P2-21** Gluten free diet and survival in adult patients with celiac disease : Cohort Study
Ferdaouss Lamarti, Rabat, Morocco
- P2-23** Clinical Spectrum of Celiac Disease in Adults at a Tertiary Care Hospital in Karachi, Pakistan.
Verda Arshad, Karachi, Pakistan
- P2-24** Phenotypic and genotypic differences between familial and sporadic celiac disease
Laura Airaksinen, Tampere, Finland
- P2-25** HLA-DQ2 dose effect on clinical picture of celiac disease
Laura Airaksinen, Tampere, Finland
- P2-26** Characterizing the Phenotype of Very Early Onset Celiac Disease
Arunjot Singh, Philadelphia, United States
- P2-27** A sex-based comparison of initial presentation and disease severity in celiac disease
Stephanie Moleski, Philadelphia, United States
- P2-28** Exploring the profile of celiac disease between adult and pediatric celiac patients
Efrat Broide, Zerifine, Israel
- P2-29** Infantile Onset Celiac Disease is Different from Celiac Disease presenting in older children
Sadhna Bhasin Lal, Chandigarh, India
- P2-30** Spectrum Of Presentation in children with Celiac Disease in the Celiac Belt Of India
Sadhna Bhasin Lal, Chandigarh, India
- P2-32** Correlation Between Total IgA and Tissue Transglutaminase IgA antibodies
Stine Dydensborg Sander, Odense, Denmark
- P2-33** Prevalence of celiac disease among school-aged children in Algiers
Manoubia Bensmina, Algiers, Algeria

- P2-34** Co-occurrence of Celiac Disease and Type 1 Diabetes in diverse ethnic groups at the University of Chicago
Valentina Discepolo, Chicago, United States

EPIDEMIOLOGY/ENVIRONMENTAL TRIGGERS

TOUR 2: THURSDAY, SEPTEMBER 5TH FROM 05:00 PM TO 06:00 PM

POSTER TOUR LEADERS:

Carin Andrén Aronsson, Malmö, Sweden

Valerie Byrnes, Boston, United States

- P3-01** Symptoms, Gluten Free Diet (GFD) Adherence, and Laboratory Data Do Not Predict Duodenal Mucosal Healing in Celiac Disease (CeD)
Marie Robert, New Haven, United States
- P3-02** Anxiety in treated adult celiac patients and the effect of duration of gluten-free diet on its improvement
Mohammad Rostami-Nejad, Tehran, Iran
- P3-03** Screening for celiac disease in Tunisian patients with chronic hepatitis C
Syrine Saffar, Sousse, Tunisia
- P3-04** Development of a Sequence Searchable Celiac Database of Peptides and Proteins for Risk Assessment of Novel Food Proteins
Richard E Goodman, Lincoln, United States
- P3-05** Mice colonized with duodenal microbiota of DR3-DQ2 positive individuals without celiac disease exhibit effective gluten metabolic capacity
Alberto Caminero, Hamilton, Canada
- P3-06** First-degree relatives of celiac disease patients have increased seroreactivity to serum microbial markers
Liisa Viitasalo, Tampere, Finland
- P3-07** Prospective Longitudinal Gut Metagenomic Analysis Suggests An Altered Microbiome Composition and Function in Infants Prior to Celiac Disease Onset
Maureen M Leonard, Boston, United States
- P3-08** Link between patients with likely celiac disease and positive serology for Lyme disease
F. Ramzi Asfour, San Rafael, United States
- P3-10** Comparison of R5 and G12 antibody-based ELISA methods for the determination of gluten concentration in routine gluten-free food products
Anil Verma, Ancona, Italy
- P3-11** Season of birth and early life events on the risk of celiac disease in genetically at-risk children: TEDDY study
Anna Laitinen, Tampere, Finland
- P3-12** Probiotics: If it does not help it does not do any harm in celiac disease. Really?
Aaron Lerner, Wendelsheim, Germany
- P3-13** Microbial Transglutaminase is Beneficial to Food Industries but a Caveat to Public Health
Aaron Lerner, Wendelsheim, Germany
- P3-14** Gluten content estimation in unlabeled and labeled gluten-free food products and commonly used food items consumed by celiac disease patients
Wajiha Mehtab, Delhi, India
- P3-15** Comparison of early life exposure to enterovirus between children who later developed celiac disease and healthy controls
Kärt Simre, Tartu, Estonia

POSTER SESSIONS



- P3-16** Comparison of cost and nutritional composition of gluten-free food with their gluten containing counterparts
Wajiha Mehtab, Delhi, India
- P3-17** Do Canadian adults following a gluten-free diet need supplements to meet their nutritional requirements?
Richa Chibbar, Boston, United States
- P3-18** Celiac disease and inflammatory bowel disease in patients with IgA nephropathy over time
Marleena Repo, Tampere, Finland
- P3-20** The Intestinal Microbiome in Pediatric Celiac Disease Patients: before diagnosis and one year later in relationship to symptoms and anti-tissue transglutaminase (aTTG) serology
Dory Sample, Edmonton, Canada
- P3-21** Determination of gluten traces in the daily gluten-free diet of children with celiac disease: a quantitative analysis.
Elena Lionetti, Ancona, Italy
- P3-22** Gluten free Vs Gluten-containing bread lipid profile and sodium content: results from a comparative market study
Anna Gibert, Barcelona, Spain
- P3-23** Prospective study of smoking in pregnancy and risk of celiac disease in offspring
Karl Mårild, Gothenburg, Norway
- P3-24** Has gluten recently changed in composition or processing?
Katharina Scherf, Freising, Germany
- P3-25** Parechovirus infections and increased risk of celiac disease: nested case-control study within the MIDIA longitudinal birth cohort
Ketil Størdal, Oslo, Norway
- P3-26** Cord blood metabolites and risk of coeliac disease in childhood
Ketil Størdal, Oslo, Norway
- P3-27** Serum antibodies to Type 1 Lang reovirus, but not enterovirus or rotavirus, are increased in children with celiac disease
Michael Fitzpatrick, Oxford, United Kingdom
- P3-28** Characterization of Amylase trypsin inhibitors from different wheat species
Massimiliano Cuccioloni, Camerino, Italy
- P3-29** Celiac Disease Adherence Test does not detect short term dietary adherence to gluten-free diet
Wajiha Mehtab, Delhi, India
- P3-30** Wheat amylase trypsin inhibitors (ATI) negatively affect intestinal microbiota and aggravate experimental colitis
Johannes Matzner, Mainz, Germany
- P3-31** Impact of germination on gluten, amylase inhibition and immune stimulatory potential of amylase trypsin inhibitors (ATIs) in different wheats
Manjusha Neerukonda, Mainz, Germany
- P3-33** Wheat amylase trypsin inhibitors (ATI) promote liver fibrosis in a murine model of biliary fibrosis
Muhammad Ashfaq-Khan, Mainz, Germany

- P3-34** Nutritional wheat amylase trypsin inhibitors (ATI) promote murine non-alcoholic steatohepatitis and the metabolic syndrome
Muhammad Ashfaq-Khan, Mainz, Germany

GLUTEN-FREE-DIET MANAGEMENT/COPING

TOUR 4: FRIDAY, SEPTEMBER 6TH FROM 05:10 PM TO 06:00 PM

POSTER TOUR LEADERS:

Margreet Wessels, Arnhem, Netherlands
Aaron Lerner, Wendelsheim, Germany
Katri Lindfors, Tampere, Finland
Valentina Discepolo, Chicago, United States

- P4-01** Use of micro-CT imaging of intestinal biopsies to improve the diagnostics of celiac disease
Johannes Virta, Tampere, Finland
- P4-02** Celiac Dietary Adherence Test simplifies determining adherence to gluten-free diet
Katarina Johansson, Umeå, Sweden
- P4-03** Delusion-Like Beliefs in Celiac Disease: A Qualitative Investigation
Rose-Marie Satherley, London, United Kingdom
- P4-04** Assessing Gluten Free Diet Adherence using CDAT and Biagi Questionnaires in Patients with Celiac Disease
Hugo A Penny, Sheffield, United Kingdom
- P4-05** A Quantitative Analysis of Gluten Contamination in Everyday School Supplies and Concern for Children with Celiac Disease
Vanessa Weisbrod, Washington D.C., United States
- P4-06** An Educational App to Support the Gluten-Free Diet In Patients With Celiac Disease
Vanessa Weisbrod, Washington D.C., United States
- P4-07** Associations between executive skills and daily activities while maintaining a gluten free diet
Sonya Meyer, Haifa, Israel
- P4-08** A Family Affair: The Impact of Managing a Child's Celiac Disease on Caregivers
Mary Shull, Aurora, United States
- P4-09** Daily life decision making in pediatric celiac disease: What are the decisions and who makes them?
Sonya Meyer, Haifa, Israel
- P4-10** Prescribing gluten-free foods: the impact of policy changes on quality of life
Helen Crocker, Oxford, United Kingdom
- P4-11** Guidelines to determine Follow-up Intervals for Celiac Disease based on data mining techniques
Alfonso Rodriguez-Herrera, Kilkeny, Spain
- P4-12** Utility of Symptom Severity, Frequency, and Lability in Predicting Serology Status And Villous Injury in Adults with Treated Celiac Disease
Adam Bledsoe, Rochester, United States
- P4-13** A score to identify celiac patients who need a follow-up biopsy
Annalisa Schieppati, Pavia, Italy



POSTER SESSIONS

- P4-14** Perceived Psychosocial Distress Improves in Youth and their Parents after Diagnosis of Celiac Disease
Shayna Coburn, Washington D.C., United States
- P4-15** Psychological Needs and Services in a Multidisciplinary Celiac Disease Clinic
Shayna Coburn, Washington D.C., United States
- P4-16** Occasional ingestions of gluten are tolerated in a group of patients with celiac disease
Luca Elli, Milano, Italy
- P4-17** Development and technical validation of tetramer staining for use as biomarker for assessing gluten-specific T cells in clinical studies
Glennnda M. Smithson, Cambridge, United States
- P4-18** A telephone clinic improves gluten-free dietary adherence in adults with celiac disease
Yvonne Jeanes, London, United Kingdom
- P4-19** Novel Celiac Disease Program Model Improves Follow-Up Adherence
Angie Almond, Winston-Salem, United States
- P4-20** Celiac Disease and the Family : A Mixed Methods Systematic Review
Rose-Marie Satherley, London, United Kingdom
- P4-21** Coexisting type 1 diabetes increases the risk of dietary lapses in adult celiac disease patients diagnosed in childhood
Laura Kivelä, Tampere, Finland
- P4-22** Patients with celiac disease are at high risk of metabolic syndrome and fatty liver
Govind Makharia, New Delhi, India
- P4-23** Assessment of Knowledge of Gluten-Free Diet Amongst Food Handlers in a Health Care Institution
Tyler Mullen, Halifax, Canada
- P4-24** The role of low FODMAP plus gluten free diet on the quality of life of irritable bowel syndrome patients
Mohammad Rostami-Nejad, Tehran, Iran
- P4-25** The awareness of health care professionals for diagnosis and treatment of celiac disease compared with celiac patients
Farnoush Barzegar, Tehran, Iran
- P4-27** The Milano questionnaire: a new dietary score for evaluation of compliance to gluten free diet in patients with celiac disease
Luca Elli, Milano, Italy
- P4-29** High prevalence of persisting symptoms, fatigue and reduced quality of life among treated adult celiac patients in a national cross-sectional study
Frida Van Meegen, Oslo, Norway
- P4-30** Factors associated with non adherence to gluten free diet in adults celiac patients in Israel
Dana Zelnik Yovel, Zerifine, Israel

- P4-31** Gall Bladder Dysfunction In children With Celiac Disease
Sadhna Bhasin Lal, Chandigarh, India
- P4-32** Gluten-Free Global Threshold Wars - How Safe is Safe?
Paul Valder, Toronto, Canada
- P4-33** High Rates of Depression in Adolescent Celiac Patients
Ritu Verma, Chicago, United States
- P4-35** A Real-Life Assessment of Gluten Cross-Contact In A Shared Kitchen Environment
Vanessa Weisbrod, Washington D.C., United States
- P4-36** A qualitative exploration of what people living with celiac disease think about their long-term follow up care
Rosie Cooper, Derby, United Kingdom
- P4-37** Healthcare Professionals' Views On The Long-term Follow Up Of Celiac Disease: A Qualitative Study
Rosie Cooper, Derby, United Kingdom
- P4-38** Different mineral and vitamin content in gluten free products comparing to gluten-containing counterparts
Idoia Larretxi, Vitoria, Spain
- P4-39** Tools for nutritional education in the field of gluten-free diet
Idoia Larretxi, Vitoria, Spain
- P4-40** FODMAP consumption among celiac people and its relationship with the gastrointestinal symptomatology
Idoia Larretxi, Vitoria, Spain
- P4-41** Serum IgA anti-tissue transglutaminase antibody trend of normalization in response to the gluten-free diet at short-term follow-up evaluations
Chiara Monachesi, Ancona, Italy

NEW TREATMENTS/NEW DIAGNOSTIC METHODS

TOUR 3: FRIDAY, SEPTEMBER 6TH FROM 12:15 PM TO 01:15 PM

POSTER TOUR LEADERS:

Iris Jonkers, Groningen, Netherlands
Caroline Meijer, Leiden, Netherlands
Tobias Freitag, Helsinki, Finland
Jason Tye-din, Victoria, Australia

- P5-01** Relative rates of gluten digestion by nine commercial dietary digestive supplements
Gregory Tanner, Elwood, Australia
- P5-02** Concordance of Bulb and Distal Duodenum in Celiac Disease Follow Up Biopsies: Limited Clinical Relevance of Bulb Only Persistent Mucosal Injury
Marie Robert, New Haven, United states
- P5-03** Utility of PAXgene molecular fixative for tissue-based histological, immunohistochemical and RNA gene expression assays of duodenal biopsies in celiac disease
Juha Taavela, Jyväskylä, Finland
- P5-04** Assessing Gluten Free Diet Adherence using Gluten Immunogenic Peptides in the urine of patients with Celiac Disease: First UK Pilot Study
Hugo A Penny, Sheffield, United Kingdom
- P5-05** Towards predictive circulating biomarkers for celiac disease - a next-generation sequencing microRNA transcriptomics approach
Ineke Tan, Groningen, Netherlands

POSTER SESSIONS



- P5-06** Establishing kit-independent calibrators for measuring serum transglutaminase 2 antibody concentrations for the prediction of celiac disease
Rita Elek, Debrecen, Hungaria
- P5-07** Use of Enteric-Release Budesonide in Non-Responsive Celiac Disease
Amelie Therrien, Boston, United States
- P5-08** Investigation of binding properties and kinetics of antibodies against deamidated gliadin peptides from celiac and non-celiac subjects
Ádám Diós, Debrecen, Hungaria
- P5-09** Analysis of faecal Gluten Immunogenic Peptides to determine gluten intake during the diagnosis of celiac disease and in the transition to a gluten-free diet
Remedios Domínguez, Sevilla, Spain
- P5-10** Stratification of a Large Cohort of Hungarian Celiac Patients at Diagnosis and Follow-up by a New Particle-Based Multi-Analyte Assay
Gary Norman, San Diego, United States
- P5-11** Quantitative Histology-Based Classification System for Assessment of the Intestinal Mucosal Histological changes in Patients with Celiac Disease
Prasenjit Das, New Delhi, India
- P5-12** I-FABP - serological biomarker of an impaired epithelial barrier in children with type 1 diabetes mellitus and celiac disease
Bożena Cukrowska, Warsaw, Poland
- P5-13** Endopeptidase-40 (E40), a novel glutenase from the actinomycete Actinoallomurus strain A8
Linda Cavaletti, Gerenzano, Italy
- P5-14** The microbial endopeptidase-40 (E40) efficiently neutralizes the T cell stimulatory activity of gluten proteins
Carmen Gianfrani, Naples, Italy
- P5-15** Analysis of gluten immunogenic peptides in faeces to assess adherence to the gluten free diet in celiac patients.
Ester Donat, Valencia, Spain
- P5-16** Epicutaneous Immunotherapy Suppresses Gluten Dependent Inflammation In A Mouse Model Of Celiac Disease
Eric Marietta, Rochester, United States
- P5-17** Efficacy Of Pancreatic Enzyme Supplementation For Symptom Control In Non-Responsive Celiac Disease Patients
Caitlin Barrett, Boston, United States
- P5-20** Real life patterns of dietary transgressions in long-term gluten-free diet treated celiac patients by using GIP excretion
Sonia Niveloni, Buenos Aires, Argentina
- P5-21** Celiac Facts - Online-Courses for Health Care Professionals and Patients
Katharina Julia Werkstetter, Munich, Germany
- P5-22** Bifidobacterium infantis NSL Super Strain in highly symptomatic celiac disease patients on long-term gluten-free diet. A pilot study
Sonia Niveloni, Buenos Aires, Argentina
- P5-23** AGY for Patients with Symptomatic Celiac Disease: Protocol for a Randomized, Placebo-controlled Phase II Trial
Dory Sample, Edmonton, Canada

- P5-24** CD38 expression on gluten-specific CD4+ T cells is a sensitive biomarker for gluten exposure in celiac disease patients on a gluten-free diet
Louise Fremgaard Risnes, Oslo, Norway
- P5-25** A novel artificial intelligence based approach to the diagnosis of celiac disease, based on T-cell receptor repertoires
Elizabeth Soilleux, Cambridge, United Kingdom
- P5-26** The enzyme activity of normal structure of small intestinal mucosa in adult celiac disease patients, followed gluten-free diet
Svetlana Bykova, Moscow, Russia
- P5-27** Tissue Transglutaminase Immunoglobulin A versus Duodenal Mucosal Biopsies—How to Best Assess Duodenal Healing in Pediatric Celiac Disease and Eosinophilic Esophagitis
Lisa Fahey, Philadelphia, United States
- P5-29** Milk protein-induced villous atrophy and elevated serologies in four children with celiac disease on a gluten-free diet
Ritu Verma, Chicago, United states
- P5-30** Predictors for mucosal recovery in children with Celiac Disease: tTG is not the answer
Sadhna B Lal, Chandigarh, India
- P5-31** Latiglutenase Treatment for Celiac Disease: Symptom and Quality of Life Improvement for Seropositive Patients on a Gluten-Free Diet
Jack Syage, Newport Beach, United States
- P5-32** Minimally-invasive Method for Monitoring Intestinal Villous Health in Recovering Celiac Disease Patients
Jennifer Sealey Voyksner, Durham, United States
- P5-33** Specific c receptor targeting blocks reprogramming of human tissue-resident cytotoxic lymphocytes by IL-15 and IL-21
Valentina Discepolo, Chicago, United States

OMICS & PATHOGENESIS

TOUR 3: FRIDAY, SEPTEMBER 6TH FROM 12:15 PM TO 01:15 PM

POSTER TOUR LEADERS:

Fleur Du Pre, Oslo, Norway
Valerie Abadie, Chicago, United States
Alberto Caminero Fernandez, Hamilton, Canada

- P6-01** Decreased expression of the gluten-degrading lysosomal protease Cathepsin S and the cytokine IL-27 in monocytes of pediatric celiac disease patients
Lea Costes, Rotterdam, Netherlands
- P6-02** Draft diseasome of the 33-mer gliadin peptide
Albert Garcia-Quintanilla, Seville, Spain
- P6-03** Delineating Causal SNPs in Celiac Disease Using SuRE-SNP
Roeland Broekema, Groningen, Netherlands
- P6-04** New Biophysical and Molecular Approach to Understand Gluten-related Disorders
Veronica Dodero, Bielefeld, Germany
- P6-05** The influence of food processing on the release profile of celiac immunogenic peptides from food matrices
Olivia Ogilvie, Auckland, New Zealand



POSTER SESSIONS

P6-06 Celiac disease-on-chip: Modeling a multifactorial disease in vitro
Renée Moerkens, Groningen, Netherlands

P6-07 Functional Study of Genes and Long Non-coding RNAs Associated with Celiac Disease with A Cell-type Specific CRISPR/Cas9 Pooled Screen
Chan Li, Groningen, Netherlands

P6-08 Comparative analysis of capability to activate a pathogenic gluten-specific T cell response by HLA DR5/DR7 and DR3/DR1 positive antigen presenting cells
Giovanna Del Pozzo, Naples, Italy

P6-09 Constitutive alterations in vesicular trafficking increase the sensitivity of cells from celiac disease patients to gliadin
Maria Vittoria Barone, Naples, Italy

P6-10 T cell receptor (TCR) clonotyping in blood and duodenal mucosa: a potential clinical biomarker of gluten response in celiac patients
Glenda M. Smithson, Cambridge, United States

P6-11 The intestinal expansion of TCR+ T cells and the disappearance of IL4+ T cells characterizes the transition from potential to overt celiac disease
Carmen Gianfrani, Naples, Italy

P6-12 Increased density of TCR+ intraepithelial lymphocytes is present in the duodenal mucosae from celiac patients in all stages of the disease and correlates with the extent of mucosal damage
Mariantonia Maglio, Naples, Italy

P6-13 ATIs from ancient diploid wheat have a reduced ability to activate gut innate immune response
Vera Rotondi Auffero, Avellino, Italy

P6-14 LPP and C1orf106 variants confer a genetic predisposition for epithelial barrier dysfunction in celiac disease
Danielle Cardoso Da Silva, Berlin, Germany

P6-15 Molecular histomorphometry as a tool to assess intestinal injury and functional screen on epithelial factors transmitting the injury in celiac disease
Valeriia Dotsenko, Tampere, Finland

P6-16 Aerobic energy production is impaired in small bowel epithelial cells in Celiac Disease
Heidi Kontro, Tampere, Finland

P6-17 Comparative analysis of in vitro digestibility and immunogenicity of gliadin proteins from T. durum and T. monococcum wheat
Gianfranco Mamone, Avellino, Italy

P6-18 Effect of celiac peripheral blood mononuclear cells on intestinal epithelial barrier function
Deborah Delbue, Berlin, Germany

P6-19 Investigating Celiac Disease Onset With Single-Cell RNA Sequencing
Aaron Daniel Ramirez-Sanchez, Groningen, Netherlands

P6-20 Identification of plasma cells as gluten peptide-presenting cells by use of peptide-MHCII-specific antibodies
Lene Høydahl, Oslo, Norway

P6-21 Epitope mapping of mouse monoclonal 885 antibody recognizing a celiac-related surface in transglutaminase 2
Dóra Csige, Debrecen, Hongria

P6-25 Study of SIgA receptors in the Caco2 intestinal epithelial cell line
Roman Goguyer-Deschaumes, Paris, France

P6-26 The Celiac Disease Northern Netherlands cohort (CeDNN): Setting up a biobank allowing multi-omics analyses
Astrid Maatman, Groningen, Netherlands

P6-27 Mechanisms of human SIgA binding to human intestinal epithelial cells
Benoît Clément, Paris, France

P6-28 Cytotoxic effects lead the onset of the gliadin-specific enteropathy in HLA-DQ8 tg mice.
Vera Rotondi Auffero, Avellino, Italy

P6-29 Further Development of a Novel in vivo Model for Celiac Disease in Mice with a Humanized Immune System
Manuel Encalada Ventura, Mainz, Germany

P6-30 Amylase Trypsin Inhibitors (ATIs): Analyses of their bioactivity and protein content in a large spectrum of wheat genotypes cultivated at 3 different locations
Valentina Curella, Mainz, Germany

P6-31 The microbiome in celiac disease: toward studying patient-specific host-microbe interactions
Jelle Slager, Groningen, Netherlands

P6-32 Clustering based approach for population level identification of Celiac disease associated T-cell receptor -chain CDR3 sequences
Päivi Saavalainen, Helsinki, Finland

P6-33 Prediction of potential celiac disease related adverse immune reactions to novel proteins in food
Antonio Fernandez Dumont, Parma, Spain

P6-34 Evaluation Of Intestinal Damage After Gluten Introduction And Prior To Seroconversion In Children Developing Celiac Disease Later In Life Data From The PreventCD Cohort
Johanna Kreutz, Maastricht, Netherlands

P6-35 Small intestinal transcriptional analysis outlines celiac disease patients heterogeneity
Valentina Discepolo, Chicago, United States

REFRACTORY CD, NON-CD ENTEROPATHIES & INTESTINAL LYMPHOMAS

TOUR 4: FRIDAY, SEPTEMBER 6TH FROM 05:10 PM TO 06:00 PM

POSTER TOUR LEADERS:

Govind Bhagat, New-york, United States

Hugo Penny, Sheffield, United Kingdom

P7-01 Use of Cladribine for Ulcerative Jejunitis: A Single-Center Experience in North America
Amelie Therrien, Boston, United States

P7-02 A capsule endoscopy and double-balloon enteroscopy sequential approach for early detection of complications in celiac disease: results of a prospective study
Luca Elli, Milano, Italy

P7-03 Small Bowel Adenocarcinoma as a complication of Celiac Disease: features of an old association in the new millennium
Giacomo Caio, Ferrara, Italy


POSTER SESSIONS



- P7-04** MicroRNA profiling in enteropathy associated T-cell lymphoma and refractory celiac disease
Luca Elli, Milano, Italy
- P7-05** Seronegative villous atrophy of unknown origin encompasses enteropathies with distinct clinical and genetic features and natural history
Annalisa Schieppati, Sheffield, United States
- P7-06** Single Cell Analysis of Refractory Celiac Disease Type II
Tessa Dieckman, Leiden, Netherlands
- P7-07** Risk of Malignancy in Patients with Celiac Disease
Manal Mahmoudi, Rabat, Morocco
- P7-08** High Health Care Utilization in Non-Responsive Celiac Disease
Shakira Yoosuf, Boston, United Kingdom
- P7-09** Non-celiac villous atrophy in children: clinical and immunohistochemical features
Renata Auricchio, Naples, Italy
- P7-12** Alemtuzumab as treatment option for RCD type II? Report of two cases.
Federica Branchi, Berlin, Germany
- P7-13** Ruxolitinib as tailored treatment for severe enterocolitis caused by STAT3 gain of function mutation
Marianna Parlato, Paris, France
- P7-14** Germline de novo mutation in immune checkpoint regulator PTPN2 causes very early onset autoimmune enteropathy by aberrant activation of JAK/STAT pathway
Marianna Parlato, Paris, France
- P7-15** Ulcerative jejunitis in celiac disease, a CELAC network study
Julie Bruneau, Paris, France
- P7-16** Body Mass Index and associated clinical variables in patients with Non-Celiac Wheat Sensitivity
Antonio Carroccio, Palermo, Italy
- P7-17** Gynecologic troubles in patients suffering with Non-Celiac Wheat Sensitivity
Antonio Carroccio, Palermo, Italy
- P7-18** A c-Myc-miRNAs circuit is deregulated in refractory celiac disease type 2 and EATL
Valentina Vaira, Milano, Italy
- P7-19** Enteropathy associated T-Cell Lymphoma incidence in refractory celiac disease type II patients treated with corticosteroids and/or chemotherapy
Sherine Khater, Paris, France



Research & Development in Gastroenterology and Hepatology



Innovative Drugs for bowel and liver diseases
Modern formulations and specially designed delivery systems ensure targeted release of the active drug.

DR. FALK PHARMA GmbH



Leinenweberstr. 5
79108 Freiburg
Germany

www.drpharmapharma.com

PRACTICAL INFORMATION



Date

The congress will be held from Thursday, September 5TH, 2019 to Saturday, September 7TH, 2019

Venue

Paris Marriott Rive Gauche Hotel & Conference Center
17, boulevard Saint-Jacques
Paris, 75014 France

Getting to the venue

From Charles de Gaulle International Airport (CDG) :



- RER B until Denfert-Rochereau then Metro Line 6 until Glaciere
- Estimated taxi fare: 55 EUR (one way)
- Bus service, fee: 17 EUR (one way)
- Subway service, fee: 10 EUR (one way)

From Paris/Orly Airport (ORY) :



- ORLYBUS until Denfert-Rochereau then walk to the hotel / or Metro Line 6 until Glaciere
- Estimated taxi fare: 30 EUR (one way)
- Bus service, fee : 7.7 EUR (one way)
- Subway service, fee : 12.05 EUR (one way)

From train stations :



- Gare d'Austerlitz : Metro Line 5 until Place d'Italie then Metro Line 6 until Glaciere
- Gare de l'Est : Metro Line 5 until Place d'Italie then Metro Line 6 until Glaciere
- Gare de Lyon : Metro Line 14 until Bercy then Metro Line 6 until Glaciere
- Gare du Nord (Eurostar) : RER Line B until Denfert-Rochereau and then Metro Line 6 until Glaciere
- Gare Montparnasse : Metro Line 6 until Glaciere
- Gare Saint Lazare : Metro Line 14 until Bercy then Metro Line 6 until Glaciere

Gala Dinner

Boat cruise on Seine river

Friday, September 6th, 2019, 07:30 pm - 10:00 pm

Bateaux Mouches, Port de la Conférence, PONT DE L'ALMA in the 8th district in Paris



ImmusanT

DOMINANCE IN IMMUNOTHERAPY

ImmusanT is leveraging its Epitope-Specific Immuno-Therapy (ESIT) platform to discover, develop and deliver first-in-class peptide-based immune therapies to patients living with autoimmune diseases such as celiac disease, Type-1 diabetes and other human leukocyte antigen (HLA)-linked diseases

ImmusanT is also using its technology and deep understanding of the immune system to develop new diagnostics that have the potential to provide highly specific and highly accurate diagnoses of auto-immune diseases. Our first diagnostic – GC2™ – is being developed to diagnose celiac disease through a simple in vitro blood test designed to measure T-cell markers.



Dr'Schär

Innovating special nutrition.



Our mission:

**We improve
the lives of people
with special
nutritional needs**

Dr. Schär symposium

**Friday, september 6th
9.15-10.30 am**



18th International
Celiac Disease Symposium

ICDS

www.icds2019-paris.com

www.drschaer.com/fr/institute

PROVENTION BIO: INTERCEPTING AND PREVENTING IMMUNE-MEDIATED DISEASE



Provention Bio, partnered with Amgen, is launching a Phase 2b trial to test PRV-015 (AMG 714) for diet non-responsive celiac disease.



Please join us on September 5th at 12:15 pm in Scène A+B+C for a symposium **“Interleukin-15 (IL-15) in celiac disease and the therapeutic potential of the anti-IL-15 antibody PRV-015 (AMG 714)”** featuring thought leaders in celiac disease.



To learn more about us, visit www.proventionbio.com